Pasithea Therapeutics Corp (KTTA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.84
• Market Cap: $25.09M
• EPS: $-4.43
• 52-Week High: $2.34
• 52-Week Low: $0.28

Market Sentiment

Pasithea Therapeutics Corp currently has a Bearish sentiment score of -0.40.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp. (KTTA) is a Miami Beach-based biopharmaceutical company dedicated to developing innovative therapeutics targeting psychiatric and neurological disorders through psychedelic compounds. The company aims to address significant unmet medical needs, positioning itself as a leader within the burgeoning field of mental health treatments. With a robust commitment to clinical research and development, Pasithea's proprietary platform not only seeks to enhance patient outcome...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Pasithea Therapeutics Corp and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KTTA pay dividends?

Pasithea Therapeutics Corp (KTTA) does not currently pay a regular dividend.

What is KTTA's market cap?

Pasithea Therapeutics Corp (KTTA) has a market capitalization of $25.09M with a current stock price of $0.84.